$ARCT
Arcturus Therapeutics Holdings Inc. Stock $arct

$arct Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-K Financial Statement

#000156459021009872 Filed on March 01, 2021

Income Statement

Concept	2021 Q1	2020	2019 Q4
Revenue	$2.127M	$9.539M	$2.968M
YoY Change	-19.61%	-54.12%	-60.84%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.740M	$23.22M	$1.790M
YoY Change	132.46%	83.41%	-47.97%
% of Gross Profit
Research & Development	$50.05M	$57.85M	$11.99M
YoY Change	532.18%	71.96%	147.3%
% of Gross Profit
Depreciation & Amortization	$310.0K	$880.0K	$150.0K
YoY Change	72.22%	29.41%	-6.25%
% of Gross Profit
Operating Expenses	$59.79M	$81.06M	$11.99M
YoY Change	393.83%	75.07%	44.68%
Operating Profit	-$57.67M	-$71.52M	-$10.82M
YoY Change	509.45%	180.34%
Interest Expense	$1.320M	-$620.0K	-$170.0K
YoY Change	-512.5%	29.17%	-43.33%
% of Operating Profit
Other Income/Expense, Net	-$358.0K	-$361.0K
YoY Change	135.53%	-19.06%
Pretax Income	-$56.35M	-$72.15M	-$10.99M
YoY Change	476.18%	178.33%	988.12%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$56.35M	-$72.15M	-$10.99M
YoY Change	476.31%	177.59%	988.02%
Net Earnings / Revenue	-2649.08%	-756.35%	-370.25%
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.147M	-$3.552M	-$1.091M
COMMON SHARES
Basic Shares Outstanding	26.28M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q1	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$466.8M	$462.9M	$71.40M
YoY Change	684.54%	548.32%	94.55%
Cash & Equivalents	$466.8M	$462.9M	$71.35M
Short-Term Investments
Other Short-Term Assets	$1.200M	$2.800M	$38.00K
YoY Change	102.36%	250.0%	-58.7%
Inventory
Prepaid Expenses			$720.0K
Receivables	$2.000M	$2.100M	$2.179M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$470.0M	$467.8M	$74.29M
YoY Change	637.15%	529.61%	77.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.427M	$8.600M	$2.349M
YoY Change	33.29%	14.67%	18.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.200M		$263.0K
YoY Change	1100.0%		-8.68%
Other Assets	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$11.50M	$8.700M	$7.853M
YoY Change	37.81%	11.54%	231.35%
TOTAL ASSETS
Total Short-Term Assets	$470.0M	$467.8M	$74.29M
Total Long-Term Assets	$11.50M	$8.700M	$7.853M
Total Assets	$481.5M	$476.5M	$82.14M
YoY Change	567.79%	480.39%	85.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.600M	$10.80M	$5.793M
YoY Change	48.19%	86.21%	141.58%
Accrued Expenses	$29.80M	$19.40M	$7.134M
YoY Change	204.86%	340.91%	82.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.125M	$1.300M
YoY Change
Total Short-Term Liabilities	$53.30M	$49.50M	$21.32M
YoY Change	146.19%	132.39%	69.55%
LONG-TERM LIABILITIES
Long-Term Debt	$58.10M	$13.80M	$15.00M
YoY Change	286.61%	-8.0%	51.3%
Other Long-Term Liabilities	$358.0K	$16.50M	$20.00M
YoY Change	-98.05%	-17.5%	146.91%
Total Long-Term Liabilities	$358.0K	$30.30M	$15.00M
YoY Change	-97.62%	-13.43%	51.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$53.30M	$49.50M	$21.32M
Total Long-Term Liabilities	$358.0K	$30.30M	$15.00M
Total Liabilities	$128.9M	$79.90M	$56.35M
YoY Change	133.84%	41.67%	84.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$200.2M		-$71.70M
YoY Change	145.81%		59.78%
Common Stock			$15.00K
YoY Change			-92.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$352.6M	$396.6M	$25.79M
YoY Change
Total Liabilities & Shareholders Equity	$481.5M	$476.5M	$82.14M
YoY Change	567.79%	480.39%	85.85%

Cashflow Statement

Concept	2021 Q1	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	-$56.35M	-$72.15M	-$10.99M
YoY Change	476.31%	177.59%	988.02%
Depreciation, Depletion And Amortization	$310.0K	$880.0K	$150.0K
YoY Change	72.22%	29.41%	-6.25%
Cash From Operating Activities	-$42.95M	-$42.86M	-$7.540M
YoY Change	262.2%	565.03%	30.9%
INVESTING ACTIVITIES
Capital Expenditures	$118.0K	$1.742M	-$320.0K
YoY Change	-16.9%	112.96%	39.13%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$118.0K	-$1.742M	-$320.0K
YoY Change	-16.9%	112.96%	-114.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$423.8M
YoY Change		1891.82%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	47.01M	436.1M	5.040M
YoY Change	39740.68%	940.74%	-48.94%
NET CHANGE
Cash From Operating Activities	-42.95M	-42.86M	-7.540M
Cash From Investing Activities	-118.0K	-1.742M	-320.0K
Cash From Financing Activities	47.01M	436.1M	5.040M
Net Change In Cash	3.944M	391.5M	-2.820M
YoY Change	-133.19%	1030.19%	-144.27%
FREE CASH FLOW
Cash From Operating Activities	-$42.95M	-$42.86M	-$7.540M
Capital Expenditures	$118.0K	$1.742M	-$320.0K
Free Cash Flow	-$43.07M	-$44.60M	-$7.220M
YoY Change	258.9%	514.11%	30.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	arct	Net Operating Loss And Research And Development Credit Carryforwards Limitations On Cumulative Change In Ownership Period NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod	P3Y
CY2018	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201409Member
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccruedLiabilitiesCurrent
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	32-0595345
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	10628 Science Center Drive
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 250
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	City Area Code CityAreaCode	858
CY2020	dei	Local Phone Number LocalPhoneNumber	900-2660
CY2020	dei	Trading Symbol TradingSymbol	ARCT
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	462895000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71353000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2125000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2179000
CY2020Q4	arct	Prepaid Expenses And Other Receivables PrepaidExpensesAndOtherReceivables	2769000
CY2019Q4	arct	Prepaid Expenses And Other Receivables PrepaidExpensesAndOtherReceivables	758000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	467789000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	74290000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3378000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2349000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5182000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5134000
CY2019Q4	us-gaap	Equity Method Investments EquityMethodInvestments	263000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	107000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	107000
CY2020Q4	us-gaap	Assets Assets	476456000
CY2019Q4	us-gaap	Assets Assets	82143000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10774000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5793000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20639000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7134000
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	18108000
CY2019Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8397000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	49521000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6764000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72148000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	25792000
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccruedLiabilitiesCurrent
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y7D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y11M12D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P9Y7D
CY2020	dei	Entity File Number EntityFileNumber	001-38942
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q2	dei	Entity Public Float EntityPublicFloat	701400000
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26280275
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1608000
CY2019Q4	arct	Accrued Cystic Fibrosis Foundation Liability AccruedCysticFibrosisFoundationLiability	1949000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	827000
CY2020Q4	arct	Clinical Accruals Current ClinicalAccrualsCurrent	4067000
CY2019Q4	arct	Other Accrued Research And Development Expenses OtherAccruedResearchAndDevelopmentExpenses	2750000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7134000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-21811000
CY2019	us-gaap	Operating Expenses OperatingExpenses	46302000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-71524000
CY2018	us-gaap	Operating Expenses OperatingExpenses	37564000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-32000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12662000
CY2020	us-gaap	Operating Expenses OperatingExpenses	81063000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-25513000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	371000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	13642000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-25991000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-361000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-446000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-263000
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-302000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-25991000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	328000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-21785000
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.16
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1649076
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.54
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2175184
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	66.91
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	394661
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.82
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	104886
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	21.37
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3324713
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	46.03
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	59449000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	718301
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.11
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	23975000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3324713
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	46.03
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	59449000
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	89800000
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y2M12D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4200000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1900000
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1000000.0
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21782000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20760000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1478000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25991000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	818000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2726000
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	12512000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	15000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	540343000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	97445000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143816000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71668000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	396553000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	25792000
CY2019Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	15182000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	1259000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21324000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	13845000
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14995000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4025000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4850000
CY2020Q4	us-gaap	Liabilities Liabilities	79903000
CY2019Q4	us-gaap	Liabilities Liabilities	56351000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26192000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26192000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	26000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	476456000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82143000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9539000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16982000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20582000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-72148000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.55
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.15
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20305000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12069000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10069000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-72148000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-25991000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-21785000
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	33794000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-21785000
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1259000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1982000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21278000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	139000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-72148000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	423819000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2726000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	396553000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-72148000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	8970000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-25991000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-21785000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	882000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	684000
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	582000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	6764000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	1982000
CY2020	arct	Loss From Equity Method Investments LossFromEquityMethodInvestments	263000
CY2019	arct	Loss From Equity Method Investments LossFromEquityMethodInvestments	25000
CY2018	arct	Loss From Equity Method Investments LossFromEquityMethodInvestments	302000
CY2020	arct	Other Non Cash Interest Expense OtherNonCashInterestExpense	162000
CY2019	arct	Other Non Cash Interest Expense OtherNonCashInterestExpense	873000
CY2018	arct	Other Non Cash Interest Expense OtherNonCashInterestExpense	38000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-54000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2302000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4001000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2011000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	120000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-421000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4812000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3155000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	578000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	11320000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1675000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1687000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	7041000
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	159000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42861000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6445000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1742000
CY2018	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	6594000
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	30206000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1742000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-818000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	22134000
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	4945000
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9872000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	139000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	332000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	423819000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21278000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	436145000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41907000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10204000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	391542000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	34644000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11578000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71460000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36816000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25238000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	463002000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71460000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36816000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	751000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	691000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	146000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1360000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5868000
CY2018	arct	Sale Of Intangible Assets For Equity Method Investment SaleOfIntangibleAssetsForEquityMethodInvestment	590000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	169000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	240000
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	30000
CY2018	arct	Release Of Repurchase Liability For Restricted Shares ReleaseOfRepurchaseLiabilityForRestrictedShares	39000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143800000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71700000
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	107000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	107000
CY2020	arct	Lease Expiration Year LeaseExpirationYear	2025
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Significant Customers</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company limits its exposure to credit loss by placing its cash and cash equivalents with high credit quality financial institutions in instruments with short maturities. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was one customer that comprised 100% of the total accounts receivable balance at December 31, 2020 and one customer that comprised 98% of the total accounts receivable balance at December 31, 2019. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, the Company’s top four customers<span style="color:#000000;"> collectively </span>represented 94% of the Company’s total revenue. For the year ended December 31, 2019, there were four customers that collectively represented 91% of the Company’s total revenue. </p>
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	462895000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71353000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36709000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	107000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	107000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	107000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	463002000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71460000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36816000
CY2020	us-gaap	Dividends Dividends	0
CY2019	us-gaap	Dividends Dividends	0
CY2019Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	2179000
CY2020	arct	Contract With Customer Asset Additions For Revenue Recognized ContractWithCustomerAssetAdditionsForRevenueRecognized	4030000
CY2020	arct	Contract With Customer Asset Deductions For Cash Collections ContractWithCustomerAssetDeductionsForCashCollections	-4084000
CY2020Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	2125000
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	23579000
CY2020	arct	Contract With Customer Liability Additions For Advanced Billings ContractWithCustomerLiabilityAdditionsForAdvancedBillings	16579000
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-9538000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	30620000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9539000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20789000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15753000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2097000
CY2020Q4	arct	Accrued Cystic Fibrosis Foundation Liability AccruedCysticFibrosisFoundationLiability	6585000
CY2020Q4	arct	Accrued Singapore Economic Development Board Liability AccruedSingaporeEconomicDevelopmentBoardLiability	1761000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1630000
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1250000
CY2020Q4	arct	Other Accrued Research And Development Expenses OtherAccruedResearchAndDevelopmentExpenses	3249000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20639000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	882000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	684000
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	582000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6441000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4530000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3063000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2181000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3378000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2349000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1250000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	7500000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	6550000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	15300000
CY2020	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	900000
CY2019	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	900000
CY2018	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	200000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1157175
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	138377
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	94000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6764000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1982000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1259000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-72148000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-25922000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-21604000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-69000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-181000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-72148000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-25991000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-21785000
CY2020	arct	Maximum Percentage Of Likelihood Of Uncertain Tax Position Recognized To Be Sustained MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained	0.50
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.053
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	535000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.003
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.013
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.055
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	400000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	400000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	300000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	800000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1500000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	400000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1500000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	400000
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2018	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	33896000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15078000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6278000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	28000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	410000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	3230000
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1248000
CY2020Q4	arct	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1274000
CY2019Q4	arct	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1466000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1338000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	339000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	46551000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18569000
CY2020Q4	arct	Deferred Tax Liabilities Property Plant And Equipment And Intangible Assets DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets	69000
CY2019Q4	arct	Deferred Tax Liabilities Property Plant And Equipment And Intangible Assets DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets	11000
CY2020Q4	arct	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	1168000
CY2019Q4	arct	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	1326000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45314000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17232000
CY2020	arct	Net Operating Loss And Research And Development Credit Carryforwards Limitations On Cumulative Change In Ownership Minimum Percentage NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage	0.50
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.068
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.046
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.207
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.001
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1470000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.030
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1390000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1432000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.251
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.002
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.087
CY2020	arct	Effective Income Tax Rate Reconciliation Uncertain Tax Position EffectiveIncomeTaxRateReconciliationUncertainTaxPosition	-0.015
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.015
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0.285
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.674
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.007
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.011
CY2020Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P13M
CY2020Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P1M
CY2020Q1	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	The lease may be extended for one twelve-month period, and in November 2020 the Company deemed the extension option reasonably certain to be exercised and included the option in the lease terms beginning in December 2020.
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2033000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	314000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6639000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	984000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5655000
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M13D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.084
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1900000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	1200000
CY2018	us-gaap	Operating Lease Cost OperatingLeaseCost	1100000
CY2019Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11994000
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3534000
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2322000
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2333000
CY2020	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 13. Litigation</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 13, 2019, a former employee of the Company filed a complaint in San Diego County Superior Court, captioned Adonary Munoz v. Arcturus Therapeutics, Inc., et al, Case No. 37-2019-00066358-CU-PO-CTL. The lawsuit alleges sexual assault by an acquaintance of one of our employees and seeks to hold the Company liable on a number of causes of action. On January 17, 2020, a second amended complaint (“SAC”) was filed seeking $30 million in damages, including punitive damages and damages for emotional distress. The matter is scheduled for mediation on May 5, 2021. The Company believes the allegations of Ms. Munoz in her complaint are without merit, </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and intend</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to vigorously defend </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sel</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the foregoing action. However, in light of the preliminary stage of the litigation, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unable to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">estimate a potential loss or range of losses relating to this matter</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
CY2020Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	30000000
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2646000
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2238000
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7917000
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7944000
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17699000
CY2020Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24286000
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4191000
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4420000
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5572000
CY2020Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9034000
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9462000
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10042000
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-20938000
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-31082000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-9777000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-10263000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-21004000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-31104000
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.55
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.92
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.25
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14521000
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18794000
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22938000
CY2020Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24886000
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4350000
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10153000
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3318000
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2968000
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7324000
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7269000
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7053000
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3456000
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3881000
CY2019Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1791000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7616000
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-10817000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-6884000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-685000
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.76
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10095000
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10412000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6508000
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-572000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-7433000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-10989000
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13201000
CY2019Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14505000

Files In Submission

Name	View Source	Status
0001564590-21-009872-index-headers.html	Edgar Link	pending
0001564590-21-009872-index.html	Edgar Link	pending
0001564590-21-009872.txt	Edgar Link	pending
0001564590-21-009872-xbrl.zip	Edgar Link	pending
arct-10k_20201231.htm	Edgar Link	pending
arct-10k_20201231_htm.xml	Edgar Link	completed
arct-20201231.xsd	Edgar Link	pending
arct-20201231_cal.xml	Edgar Link	unprocessable
arct-20201231_def.xml	Edgar Link	unprocessable
arct-20201231_lab.xml	Edgar Link	unprocessable
arct-20201231_pre.xml	Edgar Link	unprocessable
arct-ex1029_392.htm	Edgar Link	pending
arct-ex1030_393.htm	Edgar Link	pending
arct-ex231_12.htm	Edgar Link	pending
arct-ex311_13.htm	Edgar Link	pending
arct-ex312_10.htm	Edgar Link	pending
arct-ex313_8.htm	Edgar Link	pending
arct-ex321_6.htm	Edgar Link	pending
arct-ex322_9.htm	Edgar Link	pending
arct-ex323_15.htm	Edgar Link	pending
arct-ex41_391.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gfzw24spf2qo000001.jpg	Edgar Link	pending
gfzw24spf2qo000002.jpg	Edgar Link	pending
gfzw24spf2qo000003.jpg	Edgar Link	pending
gfzw24spf2qo000004.jpg	Edgar Link	pending
gfzw24spf2qo000005.jpg	Edgar Link	pending
gfzw24spf2qo000006.jpg	Edgar Link	pending
gfzw24spf2qo000007.jpg	Edgar Link	pending
gfzw24spf2qo000008.jpg	Edgar Link	pending
gfzw24spf2qo000009.jpg	Edgar Link	pending
gfzw24spf2qo000010.jpg	Edgar Link	pending
gfzw24spf2qo000011.jpg	Edgar Link	pending
gfzw24spf2qo000012.jpg	Edgar Link	pending
gfzw24spf2qo000013.jpg	Edgar Link	pending
gfzw24spf2qo000014.jpg	Edgar Link	pending
gfzw24spf2qo000015.jpg	Edgar Link	pending
gijqbk3jmuhr000001.jpg	Edgar Link	pending
gsvzamn12xa0000001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARCT
Arcturus Therapeutics Holdings Inc. Stock $arct

2021 Q1 Form 10-K Financial Statement

#000156459021009872 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARCT Arcturus Therapeutics Holdings Inc. Stock $arct

2021 Q1 Form 10-K Financial Statement

#000156459021009872 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARCT
Arcturus Therapeutics Holdings Inc. Stock $arct